On 11 April 2024, Business Korea published that Celltrion has been granted a formulation patent (US 11 951 207) for its ZYMFENTRA®. ZYMFENTRA® is the world’s first self-developed subcutaneous injection of infliximab for treating autoimmune diseases. Celltrion claims to have exclusive rights to its subcutaneous formulation until the patent’s “expiration in 2038”.
On 17 March 2024, Celltrion USA launched ZYMFENTRA™ (infliximab-dyyb), the first US Approved subcutaneous formulation of infliximab (approved by the U.S. FDA in 2023).